A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladder
Open Access
- 17 October 2008
- Vol. 113 (9), 2471-2477
- https://doi.org/10.1002/cncr.23848
Abstract
BACKGROUND. Neoadjuvant cisplatin‐based chemotherapy improves survival in muscle‐invasive urothelial cancer, with MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) considered the standard regimen. Gemcitabine plus cisplatin (GC) has similar efficacy and less toxicity than MVAC in metastatic disease, but is untested as neoadjuvant treatment. METHODS. The authors retrospectively evaluated patients with muscle‐invasive urothelial carcinoma who received neoadjuvant GC before radical cystectomy between November 2000 and December 2006 at Memorial Sloan‐Kettering Cancer Center. Post‐therapy pathological downstaging to either residual disease at cystectomy (pT0) or no residual muscle‐invasion (<pT2, ie, pT0, pTIS, pT1), chemotherapy delivery, and disease‐free survival were the endpoints of interest. For comparison, similar endpoints were assessed in a historical cohort treated with neoadjuvant MVAC. RESULTS. Four cycles of neoadjuvant GC were given over 12 weeks (n = 42). Thirty‐nine (93%) of 42 patients received 4 cycles, with a median 91% drug delivery for cisplatin and 90% for gemcitabine. The pT0 proportion was 26% (95% confidence interval [CI], 14‐42), and no residual muscle‐invasive disease proportion (<pT2) was 36% (95% CI, 21‐52); pT0 was achieved in 28% (95% CI, 16‐42) and <pT2 in 35% (95% CI, 23‐49) of 54 MVAC‐treated patients. All 15 GC patients achieving <pT2 pathologic stage remained disease‐free at a median follow‐up of 30 months. CONCLUSIONS. Neoadjuvant GC is feasible and allows for timely drug delivery. The proportion of GC‐treated patients whose primary tumors were downstaged, with prolonged disease‐free survival and minimal or no residual disease, was similar to MVAC‐treated patients. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 21 references indexed in Scilit:
- Low Incidence of Perioperative Chemotherapy for Stage III Bladder Cancer 1998 to 2003: A Report From the National Cancer Data BaseJournal of Urology, 2007
- Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 TrialEuropean Urology, 2006
- Effect of Preoperative Delay on Survival in Patients With Bladder Cancer Undergoing Cystectomy in Quebec: A Population Based StudyJournal of Urology, 2006
- Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient DataEuropean Urology, 2005
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- A 3-week gemcitabine-cisplatin regimen for metastatic urothelial cancer.2004
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003
- Neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trialThe Lancet, 1999
- HIGH RISK OF VASCULAR EVENTS IN PATIENTS WITH UROTHELIAL TRANSITIONAL CELL CARCINOMA TREATED WITH CISPLATIN BASED CHEMOTHERAPYJournal of Urology, 1998
- HIGH RISK OF VASCULAR EVENTS IN PATIENTS WITH UROTHELIAL TRANSITIONAL CELL CARCINOMA TREATED WITH CISPLATIN BASED CHEMOTHERAPYJournal of Urology, 1998